Formulation and evaluation of porous osmotic pump-based Release System of oxybutynin

International Journal of PharmTech Research

Volumn 2, Issue 3, 2010, Pages 1723-1732

  Punitha, S ^a   Shirisha, Garaga ^a  

^a PRIST UNIVERSITY   (India)

Author keywords

Oxybutynin; Porous Osmotic Pump based Release System

Indexed keywords

CELLULOSE ACETATE; OXYBUTYNIN; SORBITOL;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; HYDRODYNAMICS; IN VITRO STUDY; OSMOTIC PUMP; POROUS OSMOTIC PUMP; WEIGHT GAIN;

EID: 77957592798     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Speers M, Bonnano C. Economic aspects of controlled drug delivery. In: Mathiowitz E, ed. Encyclopedia of Controlled Drug Delivery. New York, NY: Wiley; 1999:341-347.
2. Santus G, Baker WR. Osmotic drug delivery: a review of patent literature. J Control Release. 1995;35:1-21. DOI:10.1016/0168-3659(95)00013-X
3. Theeuwes F. Elementary osmotic pump. J Pharm Sci. 1975;64:1987-1991. PubMed DOI: 10.1002/jps.2600641218
4. Zentner GM, McClelland GA, Sutton SC. Controlle d porosity solubility- and resin-modulated osmotic drug delivery systems for release of diltiazem hydrochloride. J Control Release. 1991;16:237-244. DOI: 10.1016/0168-3659(91)90047-H
5. Zentner M, Rork GS, Himmelstein KJ. Osmotic flow through controlled porosity films: an approach to delivery of water-soluble compounds. J Control Release. 1985;2:217-229. DOI: 10.1016/0168-3659(85)90047-1
6. Zentner GM, Rork GS, Himmelstein KJ, inventors. Controlled porosity osmotic pump. US patent 4 968 507. November 6, 1990.
7. Herbig SM, Cardinal JR, Korsmeyer RW, Smith KL. Asymmetric-membrane tablet coatings for osmotic drug delivery. J Control Release. 1995;35:127-136. DOI: 10.1016/0168-3659(95)00028-7
8. Goldenberg MM. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther. 1999;21:634-642. PubMed DOI: 10.1016/S0149-2918(00)88316-2
9. Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol. 1988;35:515-520. PubMed DOI: 10.1007/BF00558247
10. Brunton LL, ed. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2006.
11. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol. 1999;39:289-296. PubMed
12. Monograph 7089. Oxybutynin Chloride. In: Budavari S, ed. The Merck Index. 12th ed. Whitehouse Station, NJ: Merck & Co; 1996.
13. Byrn SR, Xu W, Newman AW. Chemical reactivity in solid-state pharmaceuticals: formulation implications. Adv Drug Deliv Rev. 2001;48:115-136. PubMed DOI: 10.1016/S0169-409X(01)00102-8
14. Verma RK, Kaushal AM, Garg S. Development and evaluation of extended release formulations of isosorbide mononitrate based on osmotic technology. IntJPharm. 2003;263:9-24. PubMed DOI: 10.1016/S0378-5173(03)00360-0
15. Zentner GM, Rork GS, Himmelstein KJ. The controlled porosity osmotic pump. J Control Release. 1985;1:269-282. DOI: 10.1016/0168-3659(85)90003-3
16. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996;20:64-74.